Melanoma

[1]  J. Sosman,et al.  Melanoma: What do all the mutations mean? , 2018, Cancer.

[2]  D. van Klaveren,et al.  Risk stratification of sentinel node-positive melanoma patients defines surgical management and adjuvant therapy treatment considerations. , 2018, European journal of cancer.

[3]  D. Schadendorf,et al.  Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. , 2018, The Lancet. Oncology.

[4]  D. Schadendorf,et al.  Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma , 2018, The New England journal of medicine.

[5]  D. Schadendorf,et al.  Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. , 2018, The Lancet. Oncology.

[6]  A. Hauschild,et al.  Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. , 2017, European journal of cancer.

[7]  M. Shin,et al.  Genetic Alterations in Primary Acral Melanoma and Acral Melanocytic Nevus in Korea: Common Mutated Genes Show Distinct Cytomorphological Features. , 2017, The Journal of investigative dermatology.

[8]  D. Schadendorf,et al.  Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Buyse,et al.  Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II–III Melanoma Adjuvant Therapy , 2018, Journal of the National Cancer Institute.

[10]  K. Jöckel,et al.  Skin cancer rates in North Rhine-Westphalia, Germany before and after the introduction of the nationwide skin cancer screening program (2000–2015) , 2018, European Journal of Epidemiology.

[11]  Ross A Soo,et al.  De-novo and acquired resistance to immune checkpoint targeting. , 2017, The Lancet. Oncology.

[12]  S. Puig,et al.  Germline Variation at CDKN2A and Associations with Nevus Phenotypes among Members of Melanoma Families. , 2017, The Journal of investigative dermatology.

[13]  D. Schadendorf,et al.  Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. , 2017, European journal of cancer.

[14]  Jeffrey E Gershenwald,et al.  Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual , 2017, CA: a cancer journal for clinicians.

[15]  A. Ribas,et al.  Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) , 2017, The Lancet.

[16]  B. A. Van de Wiel,et al.  Immediate completion lymph node dissection in stage IIIA melanoma does not provide significant additional staging information beyond EORTC SN tumour burden criteria. , 2017, European journal of cancer.

[17]  D. Schadendorf,et al.  Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma , 2017, The New England journal of medicine.

[18]  A. Hauschild,et al.  Adjuvant Dabrafenib plus Trametinib in Stage III BRAF‐Mutated Melanoma , 2017, The New England journal of medicine.

[19]  P. Ascierto,et al.  Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma , 2017, The New England journal of medicine.

[20]  C. Berking,et al.  Results of COLUMBUS Part 2: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus ENCO in BRAF - Mutant Melanoma , 2017 .

[21]  J. Kirkwood,et al.  Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis. , 2017, European journal of cancer.

[22]  D. Schadendorf,et al.  Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Kirkwood,et al.  A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG‐ACRIN Cancer Research Group (E2607) , 2017, Cancer.

[24]  K. Kerr,et al.  Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  Ying Zhang,et al.  Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. , 2017, The Lancet. Oncology.

[26]  D. Schadendorf,et al.  Health-related quality of life results from the phase III CheckMate 067 study , 2017, European journal of cancer.

[27]  A. Gesierich,et al.  Completion Dissection or Observation for Sentinel‐Node Metastasis in Melanoma , 2017, The New England journal of medicine.

[28]  D. Coit.  The Enigma of Regional Lymph Nodes in Melanoma. , 2017, The New England journal of medicine.

[29]  D. Fisher,et al.  Immune and molecular correlates in melanoma treated with immune checkpoint blockade , 2017, Cancer.

[30]  N. Reinmuth,et al.  Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. , 2017, Cancer treatment reviews.

[31]  A. Eggermont,et al.  Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  J. Utikal,et al.  Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions , 2017, Nature Communications.

[33]  M. Atkins,et al.  Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204. , 2017 .

[34]  V. Sondak,et al.  A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (U.S. Intergroup E1609): Preliminary safety and efficacy of the ipilimumab arms. , 2017 .

[35]  Robert Damoiseaux,et al.  Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression , 2017, Cell reports.

[36]  J. Utikal,et al.  Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  Catherine A. Shang,et al.  Whole-genome landscapes of major melanoma subtypes , 2017, Nature.

[38]  D. Schadendorf,et al.  Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. , 2017, The Lancet. Oncology.

[39]  Bingjin Li,et al.  Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: A meta-analysis , 2017, PloS one.

[40]  Haiying Xu,et al.  PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison , 2017, Clinical Cancer Research.

[41]  D. Schadendorf,et al.  Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. , 2017, The Lancet. Oncology.

[42]  I. Zalaudek,et al.  More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments. , 2017, European journal of cancer.

[43]  J. Utikal,et al.  Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations , 2017, Oncotarget.

[44]  C. Berking,et al.  Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[45]  K. Savage,et al.  Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  S. Menzies,et al.  Cost-Effectiveness of Skin Surveillance Through a Specialized Clinic for Patients at High Risk of Melanoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[48]  D. Schadendorf,et al.  Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. , 2016, The Lancet. Oncology.

[49]  G. Linette,et al.  Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. , 2016, The Lancet. Oncology.

[50]  A. Hauschild,et al.  Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. , 2016, The New England journal of medicine.

[51]  T. Schumacher,et al.  (Neo-)adjuvant ipilimumab + nivolumab (IPI + NIVO) in palpable stage 3 melanoma – initial data from the OpACIN trial , 2016 .

[52]  K. Jöckel,et al.  The many unanswered questions related to the German skin cancer screening programme. , 2016, European journal of cancer.

[53]  Matthew Wongchenko,et al.  Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. , 2016, The Lancet. Oncology.

[54]  T. Graeber,et al.  Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. , 2016, The New England journal of medicine.

[55]  C. Horak,et al.  Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. , 2016, The Lancet. Oncology.

[56]  A. Jemal,et al.  Cancer treatment and survivorship statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[57]  Indy S Chabra,et al.  Clinical impact of a 31-gene expression profile test for cutaneous melanoma in 156 prospectively and consecutively tested patients , 2016, Current medical research and opinion.

[58]  C. Berking,et al.  Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. , 2016, The Lancet. Oncology.

[59]  D. Whiteman,et al.  The Growing Burden of Invasive Melanoma: Projections of Incidence Rates and Numbers of New Cases in Six Susceptible Populations through 2031. , 2016, The Journal of investigative dermatology.

[60]  M. Atkins,et al.  Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG). , 2016, International journal of radiation oncology, biology, physics.

[61]  R. Scolyer,et al.  A randomized phase 2 study of nivolumab and nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases: The Anti-PD1 Brain Collaboration (ABC Study). , 2016 .

[62]  A. V. van Akkooi,et al.  Response to Wheatley et al., "Surgical excision margins in primary cutaneous melanoma: A meta-analysis and Bayesian probability evaluation", Cancer Treatment Reviews. , 2016, Cancer treatment reviews.

[63]  C. Berking,et al.  Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. , 2016, Cancer treatment reviews.

[64]  D. Bennett.  Genetics of melanoma progression: the rise and fall of cell senescence , 2016, Pigment cell & melanoma research.

[65]  J. Thomas,et al.  Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trial , 2016, The Lancet. Oncology.

[66]  A. D. Van den Abbeele,et al.  Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma , 2015, Cancer.

[67]  R. Dummer,et al.  The Genetic Evolution of Melanoma from Precursor Lesions. , 2015, The New England journal of medicine.

[68]  S. Gabriel,et al.  Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.

[69]  A. Halpern,et al.  NF1 Mutations Are Common in Desmoplastic Melanoma , 2015, The American journal of surgical pathology.

[70]  A. Gavin,et al.  Survival of patients with skin melanoma in Europe increases further: Results of the EUROCARE-5 study. , 2015, European journal of cancer.

[71]  Wei Zhou,et al.  Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. , 2015, The Lancet. Oncology.

[72]  J. Utikal,et al.  Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial , 2015, The Lancet.

[73]  S. Ariyan,et al.  Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas , 2015, Nature Genetics.

[74]  Dirk Schadendorf,et al.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[75]  J. Larkin,et al.  Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.

[76]  Steven J. M. Jones,et al.  Genomic Classification of Cutaneous Melanoma , 2015, Cell.

[77]  L. Arends,et al.  Risk of subsequent cutaneous malignancy in patients with prior melanoma: a systematic review and meta‐analysis , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[78]  Antoni Ribas,et al.  Classifying Cancers Based on T-cell Infiltration and PD-L1. , 2015, Cancer research.

[79]  G. Linette,et al.  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. , 2015, The New England journal of medicine.

[80]  P. Ascierto,et al.  Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. , 2015, The Lancet. Oncology.

[81]  G. Linette,et al.  Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. , 2015, The Lancet. Oncology.

[82]  P. Rambhatla,et al.  Socioeconomic and lifestyle factors and melanoma: a systematic review , 2015, The British journal of dermatology.

[83]  D. Schadendorf,et al.  Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  S. Menzies,et al.  Specialized surveillance for individuals at high risk for melanoma: a cost analysis of a high-risk clinic. , 2015, JAMA dermatology.

[85]  D. Schadendorf,et al.  Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.

[86]  G J Mann,et al.  Clinical practice guidelines for identification, screening and follow‐up of individuals at high risk of primary cutaneous melanoma: a systematic review , 2015, The British journal of dermatology.

[87]  A. Hauschild,et al.  Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.

[88]  N. Hayward,et al.  Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma , 2014, Nature Communications.

[89]  P. Ascierto,et al.  Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. , 2014, The New England journal of medicine.

[90]  R Hofmann-Wellenhof,et al.  Clinical performance of the Nevisense system in cutaneous melanoma detection: an international, multicentre, prospective and blinded clinical trial on efficacy and safety , 2014, The British journal of dermatology.

[91]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[92]  D. Schadendorf,et al.  TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma. , 2014, Journal of the National Cancer Institute.

[93]  Justin C. Earp,et al.  FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAFV600E Mutation , 2014, Clinical Cancer Research.

[94]  R. Elashoff,et al.  Final trial report of sentinel-node biopsy versus nodal observation in melanoma. , 2014, The New England journal of medicine.

[95]  B. Bastian.  The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. , 2014, Annual review of pathology.

[96]  H. Tsao,et al.  Melanoma susceptibility genes and risk assessment. , 2014, Methods in molecular biology.

[97]  S. Puig,et al.  Somatic BRAF and NRAS mutations in familial melanomas with known germline CDKN2A status: a GenoMEL study. , 2014, The Journal of investigative dermatology.

[98]  A. McKenna,et al.  The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. , 2014, Cancer discovery.

[99]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[100]  N. Naus,et al.  Patient survival in uveal melanoma is not affected by oncogenic mutations in GNAQ and GNA11 , 2013, British Journal of Cancer.

[101]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .

[102]  D. Schadendorf,et al.  Conjunctival Melanomas Harbor BRAF and NRAS Mutations and Copy Number Changes Similar to Cutaneous and Mucosal Melanomas , 2013, Clinical Cancer Research.

[103]  C. Berking,et al.  MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. , 2013, The Lancet. Oncology.

[104]  D. Schadendorf,et al.  TERT Promoter Mutations in Familial and Sporadic Melanoma , 2013, Science.

[105]  Lynda Chin,et al.  Highly Recurrent TERT Promoter Mutations in Human Melanoma , 2013, Science.

[106]  A. Hauschild,et al.  Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[107]  C. Berking,et al.  A nine-gene signature predicting clinical outcome in cutaneous melanoma , 2013, Journal of Cancer Research and Clinical Oncology.

[108]  M. Weinstock,et al.  Does skin cancer screening save lives? , 2012, Cancer.

[109]  Ivana K. Kim,et al.  High throughput mass spectrometry-based mutation profiling of primary uveal melanoma. , 2012, Investigative ophthalmology & visual science.

[110]  C Legrand,et al.  Availability of digital dermoscopy in daily practice dramatically reduces the number of excised melanocytic lesions: results from an observational study , 2012, The British journal of dermatology.

[111]  J. Malvehy,et al.  Genetic counseling in melanoma , 2012, Dermatologic therapy.

[112]  C. Ng,et al.  NRAS mutation status is an independent prognostic factor in metastatic melanoma , 2012, Cancer.

[113]  A. Sevko,et al.  Melanoma-induced immunosuppression and its neutralization. , 2012, Seminars in cancer biology.

[114]  Peter Boyle,et al.  Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis , 2012, BMJ : British Medical Journal.

[115]  A. Hauschild,et al.  Management of immune-related adverse events and kinetics of response with ipilimumab. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[116]  A. Sivachenko,et al.  A Landscape of Driver Mutations in Melanoma , 2012, Cell.

[117]  Matthew J. Davis,et al.  Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma , 2012, Nature Genetics.

[118]  T. Fennell,et al.  Melanoma genome sequencing reveals frequent PREX2 mutations , 2012, Nature.

[119]  M. Tucker,et al.  Melanoma induction by ultraviolet A but not ultraviolet B radiation requires melanin pigment , 2012, Nature Communications.

[120]  S. Gandini,et al.  Reviews on sun exposure and artificial light and melanoma. , 2011, Progress in biophysics and molecular biology.

[121]  John P A Ioannidis,et al.  Comprehensive field synopsis and systematic meta-analyses of genetic association studies in cutaneous melanoma. , 2011, Journal of the National Cancer Institute.

[122]  K. Flaherty,et al.  Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[123]  Axel Hoos,et al.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.

[124]  M. Mihm,et al.  The performance of MelaFind: a prospective multicenter study. , 2011, Archives of dermatology.

[125]  J. O'Brien,et al.  Mutations in GNA11 in uveal melanoma. , 2010, The New England journal of medicine.

[126]  Jianxin Shi,et al.  Genome‐wide association studies of pigmentation and skin cancer: a review and meta‐analysis , 2010, Pigment cell & melanoma research.

[127]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[128]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[129]  E. Erdei,et al.  Melanoma epidemiology and public health. , 2009, Dermatologic clinics.

[130]  U. P. S. T. Force,et al.  Screening for skin cancer: U.S. Preventive Services Task Force recommendation statement. , 2009 .

[131]  Giovanni Pellacani,et al.  In vivo reflectance confocal microscopy enhances secondary evaluation of melanocytic lesions. , 2009, The Journal of investigative dermatology.

[132]  S. Menzies,et al.  Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta‐analysis of studies performed in a clinical setting , 2008, The British journal of dermatology.

[133]  H. Haenssle,et al.  Results from an observational trial: digital epiluminescence microscopy follow-up of atypical nevi increases the sensitivity and the chance of success of conventional dermoscopy in detecting melanoma. , 2006, The Journal of investigative dermatology.

[134]  J. Fridlyand,et al.  Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.

[135]  Lisa M. Schwartz,et al.  Skin biopsy rates and incidence of melanoma: population based ecological study , 2005, BMJ : British Medical Journal.

[136]  J. Thomas,et al.  Excision margins in high-risk malignant melanoma. , 2004, The New England journal of medicine.

[137]  C. Ingvar,et al.  Long term results of a randomized study by the Swedish Melanoma Study Group on 2‐cm versus 5‐cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8–2.0 mm , 2000, Cancer.

[138]  S. Gruber,et al.  Is physician detection associated with thinner melanomas? , 1999, JAMA.

[139]  N. Cascinelli,et al.  Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial , 1998, The Lancet.

[140]  N. Cascinelli,et al.  Ambulatory narrow excision for thin melanoma (< or = 2 mm): results of a prospective study. , 1997, European journal of cancer.

[141]  M. Mihm,et al.  Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. , 1996, Annals of surgery.

[142]  F. Sim,et al.  A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma. Preliminary results , 1978, Cancer.

[143]  N. Cascinelli,et al.  Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. , 1977, The New England journal of medicine.

[144]  T. Fitzpatrick,et al.  Mitotic activity in non-neoplastic melanocytes in vivo as determined by histochemical, autoradiographic, and electron microscope studies , 1975, The Journal of cell biology.

[145]  A Breslow,et al.  Thickness, Cross‐Sectional Areas and Depth of Invasion in the Prognosis of Cutaneous Melanoma , 1970, Annals of surgery.